{"id":4658,"date":"2026-04-14T06:35:12","date_gmt":"2026-04-14T06:35:12","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/4658\/"},"modified":"2026-04-14T06:35:12","modified_gmt":"2026-04-14T06:35:12","slug":"novo-nordisk-partners-with-openai-as-ai-drug-discovery-hopes-mount","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/4658\/","title":{"rendered":"Novo Nordisk partners with OpenAI as AI drug discovery hopes mount\u00a0"},"content":{"rendered":"

People walk past a sign for Novo Nordisk\u2019s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. <\/p>\n

Tom Little | Reuters<\/p>\n

Novo Nordisk<\/a> is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday.\u00a0<\/p>\n

The partnership will enable Novo to better use AI to analyze complex datasets, identify promising new drugs, and reduce the time it takes for a medicine to move from the research stage to patient use, the company said in a statement.\u00a0<\/p>\n

“There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” said Novo CEO Mike Doustdar. “Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.”<\/p>\n

“AI is reshaping industries and in life sciences, it can help people live better, longer lives,” said OpenAI CEO Sam Altman.\u00a0<\/p>\n

This is breaking news. Please refresh for updates. <\/p>\n

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"People walk past a sign for Novo Nordisk\u2019s annual general meeting at the entrance to the venue in…\n","protected":false},"author":2,"featured_media":4659,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,25,4382,1719,1242,4381,309,148,3035,4380,1721,370],"class_list":{"0":"post-4658","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ai","8":"tag-ai","9":"tag-artificial-intelligence","10":"tag-biotech-and-pharmaceuticals","11":"tag-biotechnology","12":"tag-breaking-news","13":"tag-breaking-news-europe","14":"tag-business","15":"tag-business-news","16":"tag-health-care-industry","17":"tag-novo-nordisk-a-s","18":"tag-pharmaceuticals","19":"tag-sam-altman"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/4658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=4658"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/4658\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/4659"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=4658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=4658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=4658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}